{"id":"antipsychotic-therapy","safety":{"commonSideEffects":[{"rate":"10-20%","effect":"Weight gain"},{"rate":"5-10%","effect":"Dyslipidemia"},{"rate":"5-10%","effect":"Hyperprolactinemia"}]},"_chembl":{"chemblId":"CHEMBL4298181","moleculeType":"Gene"},"_dailymed":null,"mechanism":{"_ai_source":"groq-llama-8b","explanation":"Antipsychotic medications like this one work by blocking dopamine D2 receptors in the brain, which helps to reduce symptoms of psychosis.","oneSentence":"Antagonizes dopamine D2 receptors","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T04:53:18.533Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Schizophrenia"},{"name":"Bipolar disorder"}]},"trialDetails":[{"nctId":"NCT07130500","phase":"NA","title":"Incentives and Long-Acting Injectable Adherence After Involuntary Hospitalization","status":"ENROLLING_BY_INVITATION","sponsor":"Stanford University","startDate":"2026-03-09","conditions":"Schizophrenia Disorder, Schizoaffective Disorder, Bipolar Disorder (BD)","enrollment":1000},{"nctId":"NCT06687694","phase":"","title":"Immune Mechanisms of Antipsychotic Treatment Response","status":"RECRUITING","sponsor":"King's College London","startDate":"2025-08-06","conditions":"Psychosis","enrollment":500},{"nctId":"NCT06474195","phase":"NA","title":"Cue-based Intervention in Prospective Memory and Medication Adherence.","status":"ACTIVE_NOT_RECRUITING","sponsor":"University of Pittsburgh","startDate":"2024-06-15","conditions":"Schizophrenia","enrollment":104},{"nctId":"NCT07483294","phase":"","title":"Cerebellum-based Imaging Neural Markers for Antipsychotic Response","status":"RECRUITING","sponsor":"Northwell Health","startDate":"2025-11-01","conditions":"Psychosis; Acute","enrollment":120},{"nctId":"NCT06580860","phase":"","title":"Psychiatric Multi-omics and Neuroimaging Project","status":"RECRUITING","sponsor":"mingjun Zhong","startDate":"2016-01","conditions":"Mental Disorders, Healthy Control","enrollment":1899},{"nctId":"NCT07445802","phase":"NA","title":"Medication Adherence in Severe Mental Illness: a Promotion Program","status":"NOT_YET_RECRUITING","sponsor":"Instituto de Investigación Sanitaria de la Fundación Jiménez Díaz","startDate":"2026-09","conditions":"Treatment Adherence and Compliance, Severe Mental Disorders, Bipolar Disorder (BD)","enrollment":1640},{"nctId":"NCT07446218","phase":"NA","title":"Pharmacist-led Interventions in Psychiatric Patients","status":"NOT_YET_RECRUITING","sponsor":"University of Lahore","startDate":"2026-03-01","conditions":"Mental Disorders, Metabolic Syndrome","enrollment":148},{"nctId":"NCT07445217","phase":"PHASE2","title":"Predictive Validity of the Personal and Social Performance Scale for PANSS Outcomes in Schizophrenia","status":"COMPLETED","sponsor":"Calo Psychiatric Center","startDate":"2008-03-10","conditions":"Functional Outcomes","enrollment":763},{"nctId":"NCT05741502","phase":"PHASE4","title":"An Exploratory Analysis of Immune and Inflammatory Response Associated With Clozapine","status":"TERMINATED","sponsor":"Ohio State University","startDate":"2023-08-16","conditions":"Treatment-resistant Schizophrenia","enrollment":5},{"nctId":"NCT07432763","phase":"NA","title":"Effects of Pomegranate Seed Oil Supplementation in Patients With Advanced Dementia","status":"COMPLETED","sponsor":"Panhellenic Federation of Alzheimer's Disease and Related Disorders","startDate":"2024-05-01","conditions":"Urinary Tract Infections (UTIs), Urinary Tract Infection, Recurrent, Antipsychotics Discontinuation","enrollment":18},{"nctId":"NCT05356013","phase":"PHASE2","title":"Caplyta in Borderline Personality Disorder","status":"COMPLETED","sponsor":"University of Chicago","startDate":"2023-05-10","conditions":"Borderline Personality Disorder","enrollment":60},{"nctId":"NCT06410508","phase":"NA","title":"Evaluation of a Brief Intervention to Improve Engagement in Early Intervention Services for Psychosis","status":"RECRUITING","sponsor":"Nova Scotia Health Authority","startDate":"2024-09-01","conditions":"Psychotic Disorders, Psychiatric Hospitalization, Engagement, Patient","enrollment":40},{"nctId":"NCT07402928","phase":"","title":"Optimistic and Pessimistic Dopamine Signals in the Human Brain: a Mapping and Modelling Study in Health and Parkinson's Disease","status":"RECRUITING","sponsor":"Danish Research Centre for Magnetic Resonance","startDate":"2025-06-02","conditions":"Healthy, Parkinson, Medication Administration","enrollment":140},{"nctId":"NCT05110157","phase":"PHASE3","title":"Journey Study: Evaluate the Efficacy, Safety, and Tolerability of Valbenazine as Adjunctive Treatment for Schizophrenia","status":"COMPLETED","sponsor":"Neurocrine Biosciences","startDate":"2021-11-29","conditions":"Schizophrenia","enrollment":442},{"nctId":"NCT07386483","phase":"NA","title":"Strategic Timing of Resistance Training to Guard Against Antipsychotic-Induced Metabolic Syndrome","status":"NOT_YET_RECRUITING","sponsor":"University College Dublin","startDate":"2026-02-01","conditions":"Psychosis","enrollment":40},{"nctId":"NCT00183625","phase":"PHASE4","title":"Supported Employment and Skills Training in Conjunction With Pharmacotherapy in Schizophrenia Patients","status":"COMPLETED","sponsor":"University of California, Los Angeles","startDate":"2000-06","conditions":"Schizophrenia","enrollment":107},{"nctId":"NCT04860830","phase":"PHASE3","title":"CONNEX-3: A Study to Test Whether Iclepertin Improves Learning and Memory in People With Schizophrenia","status":"COMPLETED","sponsor":"Boehringer Ingelheim","startDate":"2021-08-09","conditions":"Schizophrenia","enrollment":609},{"nctId":"NCT04580134","phase":"PHASE4","title":"CLOZAPINE Response in Biotype-1","status":"RECRUITING","sponsor":"University of Texas Southwestern Medical Center","startDate":"2022-03-01","conditions":"Schizophrenia, Schizoaffective Disorder, Bipolar 1 Disorder","enrollment":524},{"nctId":"NCT07047651","phase":"PHASE4","title":"Τhe Combination of Pharmacotherapy With RECOVERYTRSGR and RECOVERYTRSBDGR.","status":"RECRUITING","sponsor":"Dr. Stavroula Rakitzi","startDate":"2025-06-04","conditions":"Treatment Resistant Schizophrenia, Treatment Resistant Bipolar Disorder","enrollment":40},{"nctId":"NCT05662306","phase":"PHASE4","title":"C-Cog in Early Course Schizophrenia Study","status":"TERMINATED","sponsor":"University of Miami","startDate":"2024-01-23","conditions":"Schizophrenia","enrollment":1},{"nctId":"NCT06997198","phase":"PHASE4","title":"Deutetrabenazine Treatment for Tardive Dyskinesia in Intellectual/Developmental Disabilities","status":"NOT_YET_RECRUITING","sponsor":"University Hospitals Cleveland Medical Center","startDate":"2026-03-01","conditions":"Tardive Dyskinesia, Intellectual Disability, Developmental Disabilities","enrollment":25},{"nctId":"NCT02926859","phase":"PHASE2","title":"Enhancing Recovery in Early Schizophrenia","status":"ACTIVE_NOT_RECRUITING","sponsor":"Central Institute of Mental Health, Mannheim","startDate":"2017-04-08","conditions":"Schizophrenia","enrollment":180},{"nctId":"NCT06456983","phase":"NA","title":"Maintenance ElectroConvulsive Therapy in Clozapine RESISTant Schizophrenia - the MECT-RESIST Trial","status":"RECRUITING","sponsor":"Central Institute of Mental Health, Mannheim","startDate":"2025-02-14","conditions":"Schizophrenia, Treatment Resistant Schizophrenia","enrollment":140},{"nctId":"NCT07184619","phase":"PHASE3","title":"Evenamide, a Glutamate Release Modulator, as Add-On to Standard of Care in Subjects With Documented Treatment-Resistant Schizophrenia","status":"RECRUITING","sponsor":"Newron Pharmaceuticals SPA","startDate":"2026-01-23","conditions":"Treatment-resistant Schizophrenia","enrollment":400},{"nctId":"NCT07371325","phase":"NA","title":"Efficacy of Pediococcus Acidilactici as add-on to Antipsychotic Drugs on Metabolic Syndrome Disturbances in First-episode Psychosis and Schizophrenia Spectrum Disorders. A Double-blind Placebo-controlled Trial.","status":"ACTIVE_NOT_RECRUITING","sponsor":"Manuel Jesús Cuesta Zurita","startDate":"2024-09-08","conditions":"SCHIZOPHRENIA 1 (Disorder), Metabolic Abnormalities, Postbiotic Supplement","enrollment":36},{"nctId":"NCT05208190","phase":"PHASE4","title":"Clozapine for the Prevention of Violence in Schizophrenia: a Randomized Clinical Trial","status":"RECRUITING","sponsor":"New York State Psychiatric Institute","startDate":"2022-03-17","conditions":"Schizophrenia, Schizoaffective Disorder","enrollment":280},{"nctId":"NCT07363577","phase":"PHASE3","title":"Study to Evaluate LB-102 for the Treatment of Adult Patients With Acute Schizophrenia","status":"NOT_YET_RECRUITING","sponsor":"LB Pharmaceuticals Inc.","startDate":"2026-03","conditions":"Schizophrenia","enrollment":456},{"nctId":"NCT04370730","phase":"NA","title":"Dimensional and Developmental Profiles of Psychosis in Children and Adolescents","status":"RECRUITING","sponsor":"Assistance Publique - Hôpitaux de Paris","startDate":"2021-06-02","conditions":"Schizophrenia, Psychotic Disorders","enrollment":200},{"nctId":"NCT07351240","phase":"NA","title":"The Acupuncture Treatment Effect in Patients With Schizophrenia","status":"ACTIVE_NOT_RECRUITING","sponsor":"Calo Psychiatric Center","startDate":"2025-12-16","conditions":"Mental Health","enrollment":100},{"nctId":"NCT07360665","phase":"NA","title":"Multimodal Physical Exercise Program (Physical Exercise for Psychosis) for People With Psychosis Treated With Long-Acting Injectable Antipsychotics","status":"RECRUITING","sponsor":"University of Trás-os-Montes and Alto Douro","startDate":"2026-01-01","conditions":"Psychotic Disorders, Schizophrenia Spectrum Disorders (SSD), Severe Mental Illness","enrollment":44},{"nctId":"NCT05603104","phase":"PHASE3","title":"Intensified Pharmacological Treatment for Schizophrenia, Major Depressive Disorder and Bipolar Depression After a First-time Treatment Failure","status":"RECRUITING","sponsor":"Dr. Inge Winter","startDate":"2025-04-27","conditions":"Schizophrenia and Related Disorders, Major Depressive Disorder, Bipolar Depression","enrollment":1254},{"nctId":"NCT05528224","phase":"NA","title":"Effect of SC-ICBT for Adults With OCD：A Three-Arm Randomized Controlled Trial","status":"TERMINATED","sponsor":"Shanghai Mental Health Center","startDate":"2022-09-01","conditions":"Obsessive-Compulsive Disorder","enrollment":46},{"nctId":"NCT06869187","phase":"PHASE2","title":"Study of ABX-002 for the Adjunctive Treatment of Depressive Episodes Associated With Bipolar Disorder in Adults","status":"RECRUITING","sponsor":"Autobahn Therapeutics, Inc.","startDate":"2025-03-28","conditions":"Bipolar Disorder Depression","enrollment":35},{"nctId":"NCT07162467","phase":"","title":"Tryptophan-Kynurenine Pathway Metabolism in the Pathophysiology of Cognitive Impairment in Schizophrenia.","status":"ENROLLING_BY_INVITATION","sponsor":"Tianjin Anding Hospital","startDate":"2024-02-19","conditions":"Schizophrenia","enrollment":200},{"nctId":"NCT03442101","phase":"","title":"Trajectories of Treatment Response as Window Into the Heterogeneity of Psychosis: a Longitudinal Multimodal Imaging Study","status":"ACTIVE_NOT_RECRUITING","sponsor":"University of Alabama at Birmingham","startDate":"2018-04-01","conditions":"Psychosis","enrollment":156},{"nctId":"NCT06624462","phase":"NA","title":"Effectiveness of a Pragmatic, Metabolic Care Clinic for Patients With Severe Mental Illness - The Meta Care Clinic","status":"RECRUITING","sponsor":"Bjorn H. Ebdrup","startDate":"2023-10-10","conditions":"Severe Mental Disorder, Metabolic Complication, Side-Effect;Medication","enrollment":84},{"nctId":"NCT01626859","phase":"PHASE2, PHASE3","title":"A Pharmacokinetic Study of MP-214 in Patients With Schizophrenia","status":"COMPLETED","sponsor":"Tanabe Pharma Corporation","startDate":"2012-05","conditions":"Schizophrenia","enrollment":38},{"nctId":"NCT01626872","phase":"PHASE2, PHASE3","title":"Long-Term Study of MP-214 in Patients With Schizophrenia","status":"COMPLETED","sponsor":"Tanabe Pharma Corporation","startDate":"2012-09","conditions":"Schizophrenia","enrollment":254},{"nctId":"NCT06433635","phase":"PHASE4","title":"Sequential Multiple Assignment Randomized Trial for Bipolar Depression","status":"ACTIVE_NOT_RECRUITING","sponsor":"Massachusetts General Hospital","startDate":"2024-10-01","conditions":"Bipolar I Disorder, Depression","enrollment":2726},{"nctId":"NCT05939765","phase":"","title":"Pharmacologic Treatment in Legal Offenders With Schizophrenia, a Prospective Observational Mirror Image Study.","status":"WITHDRAWN","sponsor":"Psychiatric University Hospital, Zurich","startDate":"2025-12-01","conditions":"Schizophrenia","enrollment":""},{"nctId":"NCT06581302","phase":"NA","title":"Magnetic Seizure Therapy for Psychotic Disorders","status":"RECRUITING","sponsor":"Shanghai Jiao Tong University School of Medicine","startDate":"2024-09-01","conditions":"Psychotic Disorders","enrollment":50},{"nctId":"NCT07246044","phase":"NA","title":"HD-tDCS for Adolescent Bipolar Depression Targeting S1","status":"RECRUITING","sponsor":"Jiangsu Province Nanjing Brain Hospital","startDate":"2025-09-16","conditions":"Adolescent, Bipolar Depression, tDCS","enrollment":100},{"nctId":"NCT01543321","phase":"PHASE3","title":"Xenazine in Late Dyskinetic Syndrome With Neuroleptics","status":"COMPLETED","sponsor":"Centre Hospitalier Universitaire, Amiens","startDate":"2012-05-14","conditions":"Tardive Dyskinesia","enrollment":54},{"nctId":"NCT06831942","phase":"NA","title":"Attempted Suicide Short Intervention Program for Older Adults (ASSIP-OA): An Evaluation of a Psychosocial Intervention for Suicidal Adults Aged 65+","status":"RECRUITING","sponsor":"Vastra Gotaland Region","startDate":"2025-10-01","conditions":"Suicidal Ideation, Suicide Attempt, Suicide","enrollment":132},{"nctId":"NCT06221852","phase":"NA","title":"Ketogenic and Nutritional Interventions for First Episode Bipolar Disorder","status":"RECRUITING","sponsor":"Mclean Hospital","startDate":"2024-03-12","conditions":"Bipolar I Disorder, Psychosis, Schizoaffective Disorder","enrollment":50},{"nctId":"NCT04317807","phase":"PHASE2","title":"R33: Levetiracetam in Early Psychosis","status":"COMPLETED","sponsor":"NYU Langone Health","startDate":"2020-08-27","conditions":"Early Psychosis","enrollment":65},{"nctId":"NCT06179108","phase":"PHASE2","title":"Randomized, Double-blinded, Placebo-controlled, Evaluating the Treatment With LB-102 in Patients With Acute Schizophrenia","status":"COMPLETED","sponsor":"LB Pharmaceuticals Inc.","startDate":"2023-11-29","conditions":"Schizophrenia","enrollment":359},{"nctId":"NCT06067984","phase":"PHASE3","title":"An Extension Study of a Second Course of a Digital Therapeutic for the Treatment of Experiential Negative Symptoms of Schizophrenia","status":"COMPLETED","sponsor":"Click Therapeutics, Inc.","startDate":"2023-09-12","conditions":"Schizophrenia, Negative Symptoms in Schizophrenia","enrollment":73},{"nctId":"NCT05838625","phase":"PHASE3","title":"Study of Two Digital Therapeutics for the Treatment of Experiential Negative Symptoms of Schizophrenia","status":"COMPLETED","sponsor":"Click Therapeutics, Inc.","startDate":"2023-03-31","conditions":"Schizophrenia","enrollment":464},{"nctId":"NCT07206563","phase":"PHASE1, PHASE2","title":"Penfluridol for Relapsed/Refractory Small Cell Cancers","status":"NOT_YET_RECRUITING","sponsor":"Union Hospital, Tongji Medical College, Huazhong University of Science and Technology","startDate":"2025-10-01","conditions":"Small Cell Carcinoma, Small Cell Carcinoma of Lung, Small Cell Lung Cancer ( SCLC )","enrollment":33},{"nctId":"NCT02469155","phase":"PHASE3","title":"A Trial to Assess the Antipsychotic Efficacy of ITI-007 Over 6 Weeks of Treatment","status":"COMPLETED","sponsor":"Intra-Cellular Therapies, Inc.","startDate":"2015-06","conditions":"Schizophrenia","enrollment":696},{"nctId":"NCT07085923","phase":"NA","title":"Norwegian Mental Illness Heart Health Study","status":"RECRUITING","sponsor":"Madeleine Elisabeth Angelsen","startDate":"2025-09-16","conditions":"Cardio Vascular Disease, Metabolic Syndrome (MetS), Severe Mental Disorder","enrollment":70},{"nctId":"NCT07075237","phase":"PHASE4","title":"Efficacy and Functional Recovery After Switching From Paliperidone Palmitate Injection to Oral Antipsychotics in Schizophrenia","status":"NOT_YET_RECRUITING","sponsor":"Jiangsu Province Nanjing Brain Hospital","startDate":"2025-10","conditions":"Schizophrenia","enrollment":120},{"nctId":"NCT06049953","phase":"","title":"Maternal And Infant Antipsychotic Study","status":"RECRUITING","sponsor":"Icahn School of Medicine at Mount Sinai","startDate":"2023-09-29","conditions":"Antipsychotics, Pregnancy","enrollment":200},{"nctId":"NCT05958875","phase":"PHASE4","title":"The Effect of a Six Week Intensified Pharmacological Treatment for Schizophrenia Compared to Treatment as Usual in Subjects Who Had a First-time Treatment Failure on Their First-line Treatment.","status":"RECRUITING","sponsor":"Dr. Inge Winter","startDate":"2024-08-01","conditions":"Schizophrenia and Related Disorders, Early Treatment-Resistance","enrollment":418},{"nctId":"NCT07152184","phase":"PHASE2","title":"Study Comparing Antipsychotic Dose Reduction vs. Maintenance Treatment in Patients With Schizophrenia Spectrum Disorder: a Personalized Medicine Approach","status":"NOT_YET_RECRUITING","sponsor":"University Hospital, Strasbourg, France","startDate":"2026-01-01","conditions":"Patient With Schizophrenia Spectrum Disorder, NLM Classification WM 203, Psychology:Schizophrenic Psychology, Schizophrenia Spectrum and Other Psychotic Disorders","enrollment":288},{"nctId":"NCT05590637","phase":"PHASE4","title":"Comparing Antipsychotic Medications in LBD Over Time","status":"RECRUITING","sponsor":"The University of Texas Health Science Center at San Antonio","startDate":"2022-04-22","conditions":"Parkinson's Disease Psychosis, Dementia With Lewy Bodies","enrollment":94},{"nctId":"NCT07153835","phase":"PHASE4","title":"Efficacy and Safety of Paliperidone in Schizophrenia - Bangladesh Study","status":"NOT_YET_RECRUITING","sponsor":"Sher-E-Bangla Medical College","startDate":"2025-09-01","conditions":"Schizophrenia","enrollment":505},{"nctId":"NCT04373317","phase":"PHASE4","title":"Pimavanserin vs. Quetiapine for Treatment of Parkinson's Psychosis","status":"RECRUITING","sponsor":"VA Office of Research and Development","startDate":"2022-10-24","conditions":"Parkinson's Disease Psychosis","enrollment":358},{"nctId":"NCT03121586","phase":"PHASE3","title":"Extension Study of Pimavanserin for the Adjunctive Treatment of Schizophrenia","status":"TERMINATED","sponsor":"ACADIA Pharmaceuticals Inc.","startDate":"2017-01","conditions":"Schizophrenia","enrollment":995},{"nctId":"NCT04531982","phase":"PHASE3","title":"Efficacy and Safety of Pimavanserin as Adjunctive Treatment for the Negative Symptoms of Schizophrenia","status":"COMPLETED","sponsor":"ACADIA Pharmaceuticals Inc.","startDate":"2020-08-05","conditions":"Schizophrenia","enrollment":454},{"nctId":"NCT07134816","phase":"NA","title":"Cost-utility Study of Cognitive-behavioral Management of Auditory Hallucinations in Schizophrenic Disorder","status":"NOT_YET_RECRUITING","sponsor":"University Hospital, Montpellier","startDate":"2025-08","conditions":"Auditory Hallucinations, Schizophrenia Spectrum","enrollment":240},{"nctId":"NCT06904079","phase":"NA","title":"Prediction and Intervention Effect of Rehabilitation Status for Severe Mental Disorder Patients Based on Multimodal Analysis and AI Agents","status":"RECRUITING","sponsor":"Shanghai Mental Health Center","startDate":"2024-03-12","conditions":"Severe Mental Disorder, Schizophrenia, Schizoaffective Disorder","enrollment":82},{"nctId":"NCT02634463","phase":"PHASE1","title":"Whole Blood and Plasma Sample Collection for the Development of Antipsychotic Immunoassays From Participants Taking Aripiprazole, Olanzapine, Paliperidone, or Risperidone","status":"COMPLETED","sponsor":"Janssen Research & Development, LLC","startDate":"2015-11-09","conditions":"Immunoassay, Antipsychotic","enrollment":81},{"nctId":"NCT07122531","phase":"NA","title":"Recovery With Exogenous Ketones and Antipsychotics","status":"NOT_YET_RECRUITING","sponsor":"Université de Sherbrooke","startDate":"2025-08-25","conditions":"First Episode Psychosis","enrollment":15},{"nctId":"NCT00457197","phase":"PHASE4","title":"Quetiapine for Bipolar Disorder and Alcohol Dependence","status":"COMPLETED","sponsor":"University of Texas Southwestern Medical Center","startDate":"2007-03","conditions":"Bipolar Disorder, Alcohol Dependence","enrollment":90},{"nctId":"NCT07086040","phase":"NA","title":"Effects of RAS in SZ","status":"NOT_YET_RECRUITING","sponsor":"Shu-Mei Wang","startDate":"2025-08-01","conditions":"Schizophrenia and Schizoaffective Disorder","enrollment":140},{"nctId":"NCT01825798","phase":"PHASE3","title":"Treatment of Overweight Induced by Antipsychotic Medication in Young People With Autism Spectrum Disorders (ASD)","status":"COMPLETED","sponsor":"Holland Bloorview Kids Rehabilitation Hospital","startDate":"2013-04","conditions":"Overweight, Autism Spectrum Disorder","enrollment":60},{"nctId":"NCT04761861","phase":"PHASE2","title":"Vildagliptin for Treatment of Antipsychotic-induced Dyslipidemia","status":"WITHDRAWN","sponsor":"Sadat City University","startDate":"2021-02-16","conditions":"Schizophrenia, Dyslipidemias","enrollment":""},{"nctId":"NCT06333990","phase":"PHASE3","title":"Quetiapine to Reduce Post Concussive Syndrome After Mild Traumatic Brain Injury (mTBI)","status":"RECRUITING","sponsor":"Foundation for Advancing Veterans' Health Research","startDate":"2024-07-09","conditions":"Mild Traumatic Brain Injury","enrollment":146},{"nctId":"NCT07055204","phase":"NA","title":"Cognitive Remediation Method Using Rhythmic, Vocal and Corporal Musical Learning for Schizophrenia","status":"NOT_YET_RECRUITING","sponsor":"University Hospital, Toulouse","startDate":"2026-01-04","conditions":"Schizophrenia Disorders","enrollment":120},{"nctId":"NCT06756139","phase":"NA","title":"Effects of Cognitive Behavioral Therapy Through a Mobile App on Patients With Refractory Functional Dyspepsia","status":"RECRUITING","sponsor":"Air Force Military Medical University, China","startDate":"2024-11-01","conditions":"Functional Dyspepsia, Self-help Mobile Cognitive Behavioral Therapy, Antipsychotic Drug","enrollment":88},{"nctId":"NCT06949657","phase":"NA","title":"Occurrence and Influencing Factors of Cognitive Impairment in Elderly Patients With Schizophrenia and","status":"TERMINATED","sponsor":"Third People's Hospital, Huzhou City, Zhejiang Province, China","startDate":"2023-10-13","conditions":"Schizophrenia Disorders, Cognitive Impairment, Acceptance and Commitment Therapy","enrollment":78},{"nctId":"NCT07024303","phase":"EARLY_PHASE1","title":"Measurement of Treatment Effects","status":"NOT_YET_RECRUITING","sponsor":"Matthew J O'Brien, PhD, BCBA-D","startDate":"2025-06-15","conditions":"Challenging Behavior, Autism Spectrum Disorder","enrollment":20},{"nctId":"NCT07011693","phase":"PHASE4","title":"Switching Medication and Augmentation Strategies for SSRI-Resistant Adolescent Depression（SMART-I)","status":"NOT_YET_RECRUITING","sponsor":"Xinyu Zhou","startDate":"2025-06-20","conditions":"Major Depressive Disorder (MDD)","enrollment":400},{"nctId":"NCT07011953","phase":"EARLY_PHASE1","title":"A Clinical Trial of Adjunctive Thyroxine for Avolition in Schizophrenia","status":"NOT_YET_RECRUITING","sponsor":"Peking University","startDate":"2025-07-01","conditions":"Schizophrenia, Avolition","enrollment":90},{"nctId":"NCT07001878","phase":"PHASE4","title":"Cannabis Potency Effects on Brain White Matter in Early Phase Psychosis","status":"NOT_YET_RECRUITING","sponsor":"Nova Scotia Health Authority","startDate":"2025-07-01","conditions":"Psychosis, Cannabis Use","enrollment":24},{"nctId":"NCT03526354","phase":"PHASE4","title":"Controlled Trial of Brexpiprazole For The Treatment of Co-occurring Schizophrenia and Substance Use Disorder","status":"COMPLETED","sponsor":"University of Massachusetts, Worcester","startDate":"2018-06-19","conditions":"Schizophrenia, Schizoaffective Disorder, Substance Use Disorders","enrollment":50},{"nctId":"NCT06978803","phase":"","title":"HYEEG Discourse in Psychosis: A Neurobehavioural Study","status":"RECRUITING","sponsor":"Douglas Mental Health University Institute","startDate":"2024-01-16","conditions":"Psychosis, Schizophrenia Disorders","enrollment":110},{"nctId":"NCT06754163","phase":"PHASE4","title":"Evaluating the Effect of the STEP@STAH Semaglutide Protocol on the Physical Health Measures of Atypical Antipsychotic-Treated Patients","status":"RECRUITING","sponsor":"St Andrew's Healthcare","startDate":"2025-01-01","conditions":"Obesity and Obesity-related Medical Conditions, Psychiatric Disorders","enrollment":20},{"nctId":"NCT03351244","phase":"PHASE2","title":"This Study Tests Whether BI 409306 Prevents Patients With Schizophrenia From Becoming Worse. This Study Looks at How Well Patients Tolerate BI 409306 and How Effective it is Over 6 Months","status":"TERMINATED","sponsor":"Boehringer Ingelheim","startDate":"2017-12-07","conditions":"Schizophrenia","enrollment":264},{"nctId":"NCT06245213","phase":"PHASE2","title":"A Study of ANAVEX3-71 in Adults With Schizophrenia","status":"ACTIVE_NOT_RECRUITING","sponsor":"Anavex Life Sciences Corp.","startDate":"2024-03-15","conditions":"Schizophrenia","enrollment":71},{"nctId":"NCT04478838","phase":"PHASE4","title":"\"Extended\" (Alternate Day) Antipsychotic Dosing","status":"RECRUITING","sponsor":"Centre for Addiction and Mental Health","startDate":"2022-06-06","conditions":"Schizophrenia and Related Disorders, Drug Administration Schedule, Drug Therapy","enrollment":120},{"nctId":"NCT06136936","phase":"NA","title":"A Study to Evaluate the Overall Effects of Treatment With Abbreviated CT-156 in People With Schizophrenia","status":"COMPLETED","sponsor":"Click Therapeutics, Inc.","startDate":"2023-09-20","conditions":"Schizophrenia","enrollment":53},{"nctId":"NCT05461885","phase":"NA","title":"Value of Gym-based Exercise Training for Young Adults Receiving Antipsychotic Medication: The Vega Trial","status":"ACTIVE_NOT_RECRUITING","sponsor":"Rigshospitalet, Denmark","startDate":"2022-10-25","conditions":"Affective Disorder, Psychosis","enrollment":400},{"nctId":"NCT02431702","phase":"PHASE3","title":"A Study to Compare Disease Progression and Modification Following Treatment With Paliperidone Palmitate Long-Acting Injection or Oral Antipsychotics in Participant's With Recent-onset Schizophrenia or Schizophreniform","status":"COMPLETED","sponsor":"Janssen Scientific Affairs, LLC","startDate":"2015-07-08","conditions":"Schizophrenia, Psychotic Disorders","enrollment":337},{"nctId":"NCT03666715","phase":"","title":"A Study to Analyze the Impact of Treatment With Paliperidone Palmitate on Clinical Outcomes and Hospital Resource Utilization in Adult Participants With Schizophrenia in Portugal","status":"COMPLETED","sponsor":"Janssen-Cilag Farmaceutica Ltda.","startDate":"2018-08-07","conditions":"Schizophrenia","enrollment":55},{"nctId":"NCT03629951","phase":"","title":"A Study for Schizophrenia Relapse Prediction","status":"COMPLETED","sponsor":"Janssen Research & Development, LLC","startDate":"2018-11-29","conditions":"Schizophrenia","enrollment":333},{"nctId":"NCT04940039","phase":"PHASE4","title":"A Study to Assess the Treatment of Schizophrenia With Paliperidone Palmitate in Rwandan Healthcare Settings","status":"COMPLETED","sponsor":"Janssen-Cilag International NV","startDate":"2021-07-22","conditions":"Schizophrenia","enrollment":93},{"nctId":"NCT05667961","phase":"","title":"Predictors of Functional Remission in Discharged Patients With Schizophrenia After Long-term Drug Discontinuation","status":"COMPLETED","sponsor":"Shanghai Mental Health Center","startDate":"2022-09-15","conditions":"Schizophrenia","enrollment":480},{"nctId":"NCT06936137","phase":"PHASE3","title":": EFFECT OF PROBIOTIC SUPPLEMENTATION ON ATYPICAL ANTIPSYCHOTIC INDUCED WEIGHT GAIN IN PATIENTS ATTENDING PSYCHIATRIC CLINICS AT AINSHAMS UNIVERSITY HOSPITALS (A RANDOMIZED CONTROLLED TRIAL)","status":"RECRUITING","sponsor":"Ain Shams University","startDate":"2025-04-20","conditions":"Antipsychotic Induced Weight Gain","enrollment":180},{"nctId":"NCT06558201","phase":"NA","title":"Open Label Extension Study of NCT06221852","status":"ENROLLING_BY_INVITATION","sponsor":"Mclean Hospital","startDate":"2024-08-28","conditions":"Bipolar I Disorder, Schizoaffective Disorder, Psychosis","enrollment":50},{"nctId":"NCT06451952","phase":"NA","title":"Virtual Darkness Theraphy for Agitation in Dementia","status":"RECRUITING","sponsor":"University of Bergen","startDate":"2024-09-30","conditions":"Agitation in Dementia, Including Alzheimer's Disease","enrollment":72},{"nctId":"NCT06924255","phase":"PHASE4","title":"An 8-week Open-label Study of an Accelerated and Slower Switching to Xanomeline/Trospium Following Atypical Antipsychotic Treatment in Participants With Schizophrenia","status":"NOT_YET_RECRUITING","sponsor":"Collaborative Neuroscience Research, LLC","startDate":"2025-04","conditions":"Schizophrenia Disorders","enrollment":100},{"nctId":"NCT06878833","phase":"PHASE3","title":"A Study to Evaluate the Safety and Tolerability of Long-Acting Oral Risperidone (LYN-005) in Participants With Schizophrenia or Schizoaffective Disorder","status":"WITHDRAWN","sponsor":"Lyndra Inc.","startDate":"2025-04-18","conditions":"Schizophrenia, Schizoaffective Disorder","enrollment":""},{"nctId":"NCT03510325","phase":"PHASE3","title":"Sequential Multiple-Assignment Randomized Trials to Compare Antipsychotic Treatments(SMART-CAT)","status":"COMPLETED","sponsor":"Shanghai Mental Health Center","startDate":"2019-02-12","conditions":"Schizophrenia","enrollment":762},{"nctId":"NCT06560957","phase":"NA","title":"SYNCED - SYNChronized Eating in Bipolar Depression Study","status":"NOT_YET_RECRUITING","sponsor":"University of Ottawa","startDate":"2025-04-15","conditions":"Bipolar Depression, Bipolar I Disorder, Bipolar II Disorder","enrollment":40},{"nctId":"NCT06787781","phase":"NA","title":"Metabolic and Clinical Effect of Alpha-lipoic Acid Administration in Schizophrenic Subjects","status":"COMPLETED","sponsor":"University of Messina","startDate":"2021-06-01","conditions":"Metabolic Evaluation, Cardiac Complications","enrollment":15},{"nctId":"NCT05416658","phase":"NA","title":"Shared Decision Making for Antipsychotic Medications","status":"NOT_YET_RECRUITING","sponsor":"New York State Psychiatric Institute","startDate":"2026-01-01","conditions":"Schizophrenia, Schizoaffective Disorder, Schizophreniform Disorders","enrollment":120},{"nctId":"NCT02237417","phase":"PHASE4","title":"Impact of Aripiprazole Once Monthly Medications on Changes in Brain Structure and Metabolism","status":"COMPLETED","sponsor":"University of Utah","startDate":"2014-09-01","conditions":"Schizophrenia","enrollment":47}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":1034,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_1","status":"active","brandName":"Antipsychotic therapy","genericName":"Antipsychotic therapy","companyName":"FORUM Pharmaceuticals Inc","companyId":"forum-pharmaceuticals-inc","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Antagonizes dopamine D2 receptors Used for Schizophrenia, Bipolar disorder.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}